Sinopharm Group Reveals Q1 2025 Financial Highlights

Get ahead of the market:

• Find top-performing stocks and invest more intelligently with Top Smart Score Stocks.
• Use filters, conduct analysis, and optimize your search for investment opportunities utilizing this method. Cryptonesia' Stock Screener.

Sinopharm Group Co ( (HK:1099) ) has posted an update.

Sinopharm Group Co. Ltd. announced its unaudited financial results for the first quarter of 2025, revealing a total asset increase to RMB 415.08 billion from RMB 392.67 billion at the end of 2024. The financial disclosure, required by Hong Kong and Shanghai stock exchange regulations, highlights a significant rise in accounts receivables, indicating robust business operations and potential growth in the pharmaceutical distribution sector.

Further details on Sinopharm Group Co

Sinopharm Group Co. Ltd., a publicly traded enterprise established in China, operates within the healthcare sector. This firm specializes in distributing pharmaceuticals and health-related goods, primarily serving the Chinese market.

YTD Price Performance: -14.18%

Average Trading Volume: 1,611

Technical Sentiment Signal: Buy

Current Market Cap: $7B

To get comprehensive details regarding 1099 stocks, visit Cryptonesia’ Stock Analysis page .

Disclaimer & Disclosure Report an Issue

Trending Articles

• Everyone's Focused on AMD Shares Before Q1 Earnings Release — Christopher Rolland Provides Context
• 'Top Investor Calls Archer Aviation Stock "An Intriguing Gamble",' Reports Analyst
• Tesla Shares Recover: Find Out What This Leading Investor Foresees Next

Share this post